19 Years Providing Weekly Foresight

 

The most accurate predictive report on technology and the global economy,

read by leaders in industry, finance, and government worldwide.

 

 

 

 

In This Issue     Feature: Special Letter An Innovator's Handbook: Dealing with the FDA   Step 1: Concept Definition Step 2: Product Risk Step 3: Dialog with the FDA Step 4: The Paperwork Step 5: Getting to Market Conclusion About Corinna E. Lathan   Inside SNS   Upcoming SNS Events   Where's Mark?

[Please open the attached .pdf for best viewing.]

 

   By Dr. Corinna E. Lathan

 

_____

 

Five Global Challenges

 

IV: The Failure to Self-Govern

 

 

Is this what democracy looks like? Unlikely. Mark Anderson delves into the basic problems in politics today, and how to solve them - as part of the Park City Institute / SNS / "Future in Review" Speaker Series.

 

Watch now.

 

 

Publisher's Note:  We have been delving into the future of biology, genetics, healthcare, evolutionary theory, biofeedback systems, neurophysiology, brain-inspired computing, the Quantified Self, and medical software and devices for at least a decade. But nowhere during this thread have we touched on what is often the life-or-death issue for entrepreneurs in these arenas: dealing with US regulatory agencies. 

 

In this discussion, for the first time in our history, we're providing a deep dive into the do's and don'ts of this process, in perhaps the toughest product approval agency: the Food and Drug Administration. As many SNS members are aware, the challenges behind gaining entry to the US markets where this agency has sway are so daunting that many companies, both large and small, have turned to other international markets (Germany perhaps being first) as a quicker, cheaper way to early markets. 

 

What do entrepreneurs - and F500 CEOs - need to know about getting this done right? Read on. - mra.